Tekmira Announces New Appointment to Board of Directors
News Feb 15, 2014
Tekmira Pharmaceuticals Corporation has announced the appointment of Ms. Peggy Phillips to its Board of Directors.
"Peggy's appointment and expertise is consistent with our focus on product development. We're confident that her extensive biotechnology experience, senior executive background, and considerable drug development expertise will translate to valuable contributions to our Board and company," said Dr. Mark J. Murray, Tekmira's President and CEO.
The appointment of Ms. Phillips fills the vacancy created in January 2014 when Dr. Michael Abrams resigned from the Board of Directors in order to assume his current role as Tekmira's Chief Discovery Officer. The total number of directors remains at six.
Ms. Phillips was on the Board of Immunex and served as the Chief Operating Officer from 1999 until the company was acquired by Amgen in 2002. During her sixteen-year career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales, and marketing.
As General Manager for Enbrel, she was responsible for clinical development, process development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories for ten years.
Ms. Phillips currently sits on the Board of Directors of Dynavax Technologies (Nasdaq:DVAX), a clinical stage biopharmaceutical company. Ms. Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho.
Non-Coding DNA Variants Increase Autism RiskNews
Whilst the contribution of gene variants to autism risk is well-established, the contribution of the 98% of the genome that does not code for gene sequences is still relatively unknown. Now, a new study has identified regulatory elements as potential genetic risk factors.READ MORE